Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 87

1.

Safety profile after prolonged C3 inhibition.

Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RRG, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD.

Clin Immunol. 2018 Sep 20;197:96-106. doi: 10.1016/j.clim.2018.09.004. [Epub ahead of print]

PMID:
30217791
2.

Novel Immunoassay for Complement Activation by PF4/Heparin Complexes.

Khandelwal S, Johnson AM, Liu J, Keire D, Sommers C, Ravi J, Lee GM, Lambris JD, Reis ES, Arepally GM.

Thromb Haemost. 2018 Aug;118(8):1484-1487. doi: 10.1055/s-0038-1660858. Epub 2018 Jun 30. No abstract available.

PMID:
29960275
3.

New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile.

Berger N, Alayi TD, Resuello RRG, Tuplano JV, Reis ES, Lambris JD.

J Med Chem. 2018 Jul 26;61(14):6153-6162. doi: 10.1021/acs.jmedchem.8b00560. Epub 2018 Jul 3.

PMID:
29920096
4.

Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock.

van Griensven M, Ricklin D, Denk S, Halbgebauer R, Braun CK, Schultze A, Hönes F, Koutsogiannaki S, Primikyri A, Reis E, Messerer D, Hafner S, Radermacher P, Biglarnia AR, Resuello RRG, Tuplano JV, Mayer B, Nilsson K, Nilsson B, Lambris JD, Huber-Lang M.

Shock. 2018 Feb 14. doi: 10.1097/SHK.0000000000001127. [Epub ahead of print]

PMID:
29461464
5.

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates.

Kajikawa T, Briones RA, Resuello RRG, Tuplano JV, Reis ES, Hajishengallis E, Garcia CAG, Yancopoulou D, Lambris JD, Hajishengallis G.

Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215. doi: 10.1016/j.omtm.2017.08.001. eCollection 2017 Sep 15.

6.

Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model.

Wolf-Grosse S, Rokstad AM, Ali S, Lambris JD, Mollnes TE, Nilsen AM, Stenvik J.

Int J Nanomedicine. 2017 May 23;12:3927-3940. doi: 10.2147/IJN.S136453. eCollection 2017.

7.

Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII.

Gravastrand C, Hamad S, Fure H, Steinkjer B, Ryan L, Oberholzer J, Lambris JD, Lacík I, Mollnes TE, Espevik T, Brekke OL, Rokstad AM.

Acta Biomater. 2017 Aug;58:158-167. doi: 10.1016/j.actbio.2017.05.052. Epub 2017 May 30.

8.

Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery.

Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD.

Trends Immunol. 2017 Jun;38(6):383-394. doi: 10.1016/j.it.2017.03.003. Epub 2017 Apr 14.

9.

Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS.

Primikyri A, Papanastasiou M, Sarigiannis Y, Koutsogiannaki S, Reis ES, Tuplano JV, Resuello RR, Nilsson B, Ricklin D, Lambris JD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Jan 15;1041-1042:19-26. doi: 10.1016/j.jchromb.2016.12.004. Epub 2016 Dec 6.

10.

Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD.

Immunol Rev. 2016 Nov;274(1):33-58. doi: 10.1111/imr.12500. Review.

11.

Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.

Abicht JM, Kourtzelis I, Reichart B, Koutsogiannaki S, Primikyri A, Lambris JD, Chavakis T, Holdt L, Kind A, Guethoff S, Mayr T.

Xenotransplantation. 2017 Jan;24(1). doi: 10.1111/xen.12262. Epub 2016 Sep 27.

12.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

13.

From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD.

Immunobiology. 2016 Oct;221(10):1046-57. doi: 10.1016/j.imbio.2016.06.013. Epub 2016 Jun 16. Review.

14.

Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.

Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D, Ricklin D, Lambris JD.

Semin Immunol. 2016 Jun;28(3):285-91. doi: 10.1016/j.smim.2016.03.006. Epub 2016 Mar 24. Review.

15.

Combined Inhibition of Complement and CD14 Attenuates Bacteria-Induced Inflammation in Human Whole Blood More Efficiently Than Antagonizing the Toll-like Receptor 4-MD2 Complex.

Gustavsen A, Nymo S, Landsem A, Christiansen D, Ryan L, Husebye H, Lau C, Pischke SE, Lambris JD, Espevik T, Mollnes TE.

J Infect Dis. 2016 Jul 1;214(1):140-50. doi: 10.1093/infdis/jiw100. Epub 2016 Mar 14.

16.

Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.

Maekawa T, Briones RA, Resuello RR, Tuplano JV, Hajishengallis E, Kajikawa T, Koutsogiannaki S, Garcia CA, Ricklin D, Lambris JD, Hajishengallis G.

J Clin Periodontol. 2016 Mar;43(3):238-49. doi: 10.1111/jcpe.12507. Epub 2016 Mar 3.

17.

Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.

Wang J, Wang L, Xiang Y, Ricklin D, Lambris JD, Chen G.

Clin Immunol. 2016 Jan;162:37-44. doi: 10.1016/j.clim.2015.11.002. Epub 2015 Nov 6.

18.

Applying complement therapeutics to rare diseases.

Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD.

Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1. Review.

19.

Complement inhibition decreases early fibrogenic events in the lung of septic baboons.

Silasi-Mansat R, Zhu H, Georgescu C, Popescu N, Keshari RS, Peer G, Lupu C, Taylor FB, Pereira HA, Kinasewitz G, Lambris JD, Lupu F.

J Cell Mol Med. 2015 Nov;19(11):2549-63. doi: 10.1111/jcmm.12667. Epub 2015 Sep 3.

20.

Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.

Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD.

Mol Oral Microbiol. 2016 Feb;31(1):3-17. doi: 10.1111/omi.12129. Epub 2015 Oct 7. Review.

Supplemental Content

Loading ...
Support Center